Search Results
Bleomycin
Bleomycin is FDA approved as a single agent or in proven combinations to treat people who have Hodgkin and non-Hodgkin lymphoma. Bleomycin may cause a temporary loss of hair in some people. Normal hair growth should return after treatment ends (although it may take several months).
Copanlisib
Copanlisib is FDA approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
In Loving Memory of a Cancer-Fighting Legacy: UFCW Fights Cancer in Honor of Late Staff Member
The United Food and Commercial Workers (UFCW) is one of North America’s largest labor organizations with more than 1.3 million members.
Moms In Training: Keeping on Track
Staying on track while you train for a walk or run event can be challenging at times. This is especially true for busy moms who barely have enough time to work out, let alone track their fitness progress.
One Family’s Inspiring Quest to Help Other Families Impacted By Cancer
A nasty cough and extreme fatigue first led Myrna and Lou Binder to bring their 12-year-old son, Jeff, to the doctor for an examination. But the flu-like symptoms persisted until more tests enabled the doctors to arrive at the shocking diagnosis: non-Hodgkin lymphoma. The year was 1975.
Paying Tribute to a Legacy: Executive Challenge Winners Recognized
This year’s Light The Night Executive Challenge ended with a bittersweet roundup of results. The winner, Stacey Weathers, former long-time executive director of The Leukemia & Lymphoma Society’s (LLS) New Jersey chapter, was tragically killed this past October when a tree fell on her car during a storm. Even though she isn’t here to celebrate with her LLS colleagues and family, her worthy achievement will be recognized as her legacy lives on.
A Powerful Force
Plerixafor
Plerixafor injection is FDA approved for use along with a granulocyte colony-stimulating factor (G-CSF) medication in preparation for an autologous stem cell transplant in patients with non-Hodgkin lymphoma or myeloma. Plerixafor injection works by causing certain blood cells to move from the bone marrow to the blood so that they can be removed for transplantation.
Rasburicase
Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.
A College Freshmen Faces A Cancer Diagnosis
The symptoms I habitually pushed off as stressors from my first semester of college, began to accumulate. Throughout the semester I felt less like my healthy self because of coughing, abnormal skin reactions, unexplainable fatigue and diminishing motivation.
Lomustine
Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who relapse while being treated with primary therapy or who fail to respond to primary therapy.
Nelarabine
Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.
Nivolumab
Nivolumab is FDA approved for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Crizotinib
Crizotinib is FDA approved for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Limitations of Use: The safety and efficacy of Xalkori have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
Targeted Therapy focus of LLS-hosted Symposium at ASH
As researchers gain greater understanding of how cancer works, they are becoming more adept at developing precisely targeted therapies that go after the tumor cells while sparing the healthy cells.
Today The Leukemia & Lymphoma Society (LLS) kicked off the 57th American Society of Hematology (ASH) Annual Meeting in Orlando with a satellite symposium entitled, “Molecularly Targeted Therapies for Hematologic Malignancies.”
Moving Cancer to the Back Burner
I am glad to be here. Literally.
Being a survivor is a good thing. I could have been six feet under, after being diagnosed with acute lymphoblastic leukemia (ALL) on December 16, 2000. I was 40 years old, raising two children with my husband Ron. Our daughter was almost 4 years old and our son was 16 months.
Venetoclax
Venetoclax is FDA approved
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Mosunetuzumab-axgb
Mosunetuzumab-axgb is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Asparaginase erwinia chrysanthemi (recombinant)- rywn
Rylaze® is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Nutrition Advice from a Dietitian & Blood Cancer Survivor
76-year-old Barbara Borrell is a woman who wears many hats – a 50+ year registered dietitian, nutrition consultant and educator, cancer advocate, volunteer with The Leukemia & Lymphoma Society, and a blood cancer survivor who has battled not one, not two, but three types of blood cancer.
Cladribine
Cladribine is FDA approved to treat people who have active hairy cell leukemia. It is also used to treat some other types of leukemia and lymphoma.
Ifosfamide
Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.
Teniposide
Teniposide is FDA approved along with other medicines as induction therapy to treat people who have refractory childhood acute lymphoblastic leukemia, non-Hodgkin lymphoma and other types of cancer. This medicine often causes a temporary loss of hair. After treatment with teniposide has ended, normal hair growth should return.